These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 33810032)

  • 1. Specific Patterns of Blood ILCs in Metastatic Melanoma Patients and Their Modulations in Response to Immunotherapy.
    Rethacker L; Roelens M; Bejar C; Maubec E; Moins-Teisserenc H; Caignard A
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33810032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD56
    Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
    Front Immunol; 2019; 10():14. PubMed ID: 30761123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Human ILCs and Impact of Unconventional Cytotoxic Subsets in the Pathophysiology of Inflammatory Diseases and Cancer.
    Calvi M; Di Vito C; Frigo A; Trabanelli S; Jandus C; Mavilio D
    Front Immunol; 2022; 13():914266. PubMed ID: 35720280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low baseline levels of NK cells may predict a positive response to ipilimumab in melanoma therapy.
    Tietze JK; Angelova D; Heppt MV; Ruzicka T; Berking C
    Exp Dermatol; 2017 Jul; 26(7):622-629. PubMed ID: 27892653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions.
    Mariotti FR; Quatrini L; Munari E; Vacca P; Moretta L
    Front Immunol; 2019; 10():910. PubMed ID: 31105707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NK cells and ILCs in tumor immunotherapy.
    Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
    Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Helper Innate Lymphoid Cells-Unappreciated Players in Melanoma Therapy.
    Garofalo C; Cerantonio A; Muscoli C; Mollace V; Viglietto G; De Marco C; Cristiani CM
    Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors.
    Cristiani CM; Capone M; Garofalo C; Madonna G; Mallardo D; Tuffanelli M; Vanella V; Greco M; Foti DP; Viglietto G; Ascierto PA; Spits H; Carbone E
    Front Immunol; 2022; 13():811131. PubMed ID: 35173725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses.
    Loyon R; Jary M; Salomé B; Gomez-Cadena A; Galaine J; Kroemer M; Romero P; Trabanelli S; Adotévi O; Borg C; Jandus C
    Front Immunol; 2019; 10():2121. PubMed ID: 31555301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of several activating and inhibitory receptors on CD3(-)CD56(+) NK cells in regional lymph nodes of melanoma patients.
    Vuletić A; Jurišić V; Jovanić I; Milovanović Z; Nikolić S; Konjević G
    J Surg Res; 2013 Aug; 183(2):860-8. PubMed ID: 23522458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells.
    Munari E; Quatrini L; Ciancaglini C; Eccher A; Bogina G; Moretta L; Mariotti FR
    Semin Immunol; 2022 Nov; 61-64():101660. PubMed ID: 36370672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML.
    Salomé B; Gomez-Cadena A; Loyon R; Suffiotti M; Salvestrini V; Wyss T; Vanoni G; Ruan DF; Rossi M; Tozzo A; Tentorio P; Bruni E; Riether C; Jacobsen EM; Jandus P; Conrad C; Hoenig M; Schulz A; Michaud K; Della Porta MG; Salvatore S; Ho PC; Gfeller D; Ochsenbein A; Mavilio D; Curti A; Marcenaro E; Steinle A; Horowitz A; Romero P; Trabanelli S; Jandus C
    Blood Adv; 2019 Nov; 3(22):3674-3687. PubMed ID: 31765481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innate lymphoid cells: NK and cytotoxic ILC3 subsets infiltrate metastatic breast cancer lymph nodes.
    Rethacker L; Boy M; Bisio V; Roussin F; Denizeau J; Vincent-Salomon A; Borcoman E; Sedlik C; Piaggio E; Toubert A; Dulphy N; Caignard A
    Oncoimmunology; 2022; 11(1):2057396. PubMed ID: 35371620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific phenotype and function of CD56-expressing innate immune cell subsets in human thymus.
    Gerstner S; Köhler W; Heidkamp G; Purbojo A; Uchida S; Ekici AB; Heger L; Luetke-Eversloh M; Schubert R; Bader P; Klingebiel T; Koehl U; Mackensen A; Romagnani C; Cesnjevar R; Dudziak D; Ullrich E
    J Leukoc Biol; 2016 Dec; 100(6):1297-1310. PubMed ID: 27354408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer.
    Maas RJ; Hoogstad-van Evert JS; Van der Meer JM; Mekers V; Rezaeifard S; Korman AJ; de Jonge PK; Cany J; Woestenenk R; Schaap NP; Massuger LF; Jansen JH; Hobo W; Dolstra H
    Oncoimmunology; 2020 Nov; 9(1):1843247. PubMed ID: 33224630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients.
    Konjević G; Mirjačić Martinović K; Vuletić A; Babović N
    Melanoma Res; 2010 Dec; 20(6):459-67. PubMed ID: 20938360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Helper Innate Lymphoid Cells in Human Tumors: A Double-Edged Sword?
    Tumino N; Vacca P; Quatrini L; Munari E; Moretta F; Pelosi A; Mariotti FR; Moretta L
    Front Immunol; 2019; 10():3140. PubMed ID: 32063901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients.
    Mirjačić Martinović KM; Babović NLj; Džodić RR; Jurišić VB; Tanić NT; Konjević GM
    Melanoma Res; 2014 Aug; 24(4):295-304. PubMed ID: 24769842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New miRNA Signature Heralds Human NK Cell Subsets at Different Maturation Steps: Involvement of miR-146a-5p in the Regulation of KIR Expression.
    Pesce S; Squillario M; Greppi M; Loiacono F; Moretta L; Moretta A; Sivori S; Castagnola P; Barla A; Candiani S; Marcenaro E
    Front Immunol; 2018; 9():2360. PubMed ID: 30374356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A temporal developmental map separates human NK cells from noncytotoxic ILCs through clonal and single-cell analysis.
    Vo DN; Yuan O; Kanaya M; Telliam-Dushime G; Li H; Kotova O; Caglar E; Honnens de Lichtenberg K; Rahman SH; Soneji S; Scheding S; Bryder D; Malmberg KJ; Sitnicka E
    Blood Adv; 2024 Jun; 8(11):2933-2951. PubMed ID: 38484189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.